Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Petosemtamab's phase 2 data in this setting should come by the year end.
After ZW171's exit, ZW251 enters the clinic.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
